Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis
Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis
The purpose of this study is to learn more about the role of etanercept alone or in
 combination with methotrexate on disease activity in adults with psoriatic arthritis.
The study will consist of a 30-day screening period, a 48-week double-blind treatment period
 and a 30-day safety follow-up period.

 At or after week 24, participants with an inadequate response could receive rescue therapy
 with etanercept plus methotrexate until the end of the treatment period.
Key Inclusion Criteria:

 -  Subject must have a diagnosis of psoriatic arthritis (PsA) by the Classification
 Criteria for Psoriatic Arthritis (CASPAR) criteria.

 -  Subject has ≥ 3 tender and ≥ 3 swollen joints at screening and at baseline.

 -  Subject has an active psoriatic skin lesion

 -  Subject is naïve to etanercept and any other biologic for the treatment for PsA or
 psoriasis.

 -  Subject has no prior use of methotrexate for PsA.

 -  Subject has no history of tuberculosis

 -  Subject has a negative test for tuberculosis, hepatitis B and C.

 Exclusion Criteria:

 -  Subject has known history of alcoholic hepatitis, nonalcoholic steatohepatitis or
 immunodeficiency syndromes, including human immunodeficiency virus (HIV) infection.

 -  Subject has any active infection (including chronic or localized infections) for which
 anti-infectives were indicated within 4 weeks prior to the first dose of
 investigational product.

 -  Subject has a serious infection, defined as requiring hospitalization or intravenous
 anti-infectives within 8 weeks prior to the first dose of investigational product.